Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Rydapt (midostaurin)
pCPA File Number:
21018
Negotiation Status:
Concluded with an LOI
Indication(s):
Acute Myeloid Leukemia
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CADTH Project Number:
pCODR 10108
pCPA Engagement Letter Issued:
2018-02-02
Negotiation Process Concluded:
2018-07-05